The Faces of iPSpine

Christine le maitre

Professor of Cell Biology and Tissue Regeneration, in the Biomolecular Sciences Research Centre of Sheffield Hallam Univeristy. 

Contribution to the ipspine project
Working in this consortium
Being part of the unique project

What is your team’s main scientific expertise/contribution to the iPSpine project?

With nearly 20 years of experience in researching the pathogenesis of disc degeneration. We have characterised the changes which occur during disc degeneration in the cells of the diseased disc. The advanced cell therapy developed in iPSpine (iPS-NLCs) is intended to inhibit important features of disc degeneration, and as such prevent further degeneration and even promote regeneration. Therefore, one of our major roles in the project is to develop a system within the laboratory where we can mimic the environment of the degenerative disc. Together with human disc cells derived from degenerative discs we could therefore determine the potential behaviour after the injection into the disc and identify what needs to be finetuned for ideal performance of the iPS-NLCs.



Smart biomaterials facilitate cells to survive and thrive in the degenerated environment. Within this context, for the past 10 years here in Sheffield we have developed an injectable gel, together with Professor Chris Sammon. We have shown that this gel system can inhibit factors seen in disc degeneration, mimic the mechanical behaviour of the disc, and program stem cells into disc cells. This hydrogel is one of the biomaterials under investigation within iPSpine.

How does it feel to be working in such a large consortium?

Very exciting! The funding gives us a fantastic opportunity to work on a large program for a 5-year period. This really generates a great momentum to make progress towards a new therapy for low back pain.

What do you think is unique about being part of the iPSpine project?

This project brings together such a diverse range of expertise from scientists, bioengineers, material scientists to ethical advisors, regulatory experts and essentially patient advisors and clinicians. This is the first time I have been involved in such a consortium and really gives us the opportunity to develop a new therapy.

The other faces of ipspine